Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108417
Filing Date
2025-08-14
Accepted
2025-08-14 07:23:25
Documents
66
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q prld-20250630.htm   iXBRL 10-Q 1935242
2 EX-3.1 prld-ex3_1.htm EX-3.1 82768
3 EX-31.1 prld-ex31_1.htm EX-31.1 17543
4 EX-31.2 prld-ex31_2.htm EX-31.2 17545
5 EX-32.1 prld-ex32_1.htm EX-32.1 9883
6 EX-32.2 prld-ex32_2.htm EX-32.2 10026
  Complete submission text file 0000950170-25-108417.txt   8509910

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20250630.xsd EX-101.SCH 1119454
69 EXTRACTED XBRL INSTANCE DOCUMENT prld-20250630_htm.xml XML 1687729
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39527 | Film No.: 251214309
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)